The Technical Analyst
Select Language :
Evogene Ltd [EVGN]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Evogene Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals

Evogene Ltd is listed at the  Exchange

4.08% $0.760

America/New_York / 28 mar 2024 @ 12:16


FUNDAMENTALS
MarketCap: 38.42 mill
EPS: -0.470
P/E: -1.620
Earnings Date: Mar 07, 2024
SharesOutstanding: 50.55 mill
Avg Daily Volume: 0.195 mill
RATING 2024-03-27
B-
Sell
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Neutral
P/E: Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -1.620 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.28x
Company: PE -1.620 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 0.695 - 0.845

( +/- 9.74%)
ATR Model: 14 days

Forecast: 13:56 - $0.754

Live Trading Signals (every 1 min)

Forecast 1: 12:26 - $0.762
Forecast 2: 13:16 - $0.750
Forecast 3: 13:56 - $0.754
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $0.760 (4.08% )
Volume 0.0287 mill
Avg. Vol. 0.195 mill
% of Avg. Vol 14.73 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Evogene Ltd

Last 12 Months

Last 12 months chart data with high, low, open and close for Evogene Ltd

RSI

Intraday RSI14 chart for Evogene Ltd

Last 10 Buy & Sell Signals For EVGN

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Evogene Ltd

EVGN

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Last 10 Buy Signals

Date Signal @
ROPMar 28 - 12:16$558.09
PROPCUSDMar 28 - 12:154.88
LTCUSDMar 28 - 12:16$94.20
NQUSDMar 28 - 12:0718 487
HNTUSDMar 28 - 12:15$6.10
CBKUSDMar 28 - 12:131.096
AMKTUSDMar 28 - 12:14221.00
BURGERUSDMar 28 - 12:140.883
DEGOUSDMar 28 - 12:143.67
WBETHUSDMar 28 - 12:103 679.57

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.